Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)

NCT02329080 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT02329080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02329080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
March 22, 2024
Enrollment
79 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma